A Phase 1 Study of CAN106: A Novel, Long-Acting, Anti-C5 Monoclonal Antibody in Development for Complement-Mediated Diseases

Time: 11:40 am
day: Track B - Day 1 AM


  • Exploring data supporting anti-C5 mechanism of action
  • Sharing Phase 1 single ascending dose clinical trial data in healthy volunteers
  • Progressing into the clinic for paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases